SANTA BARBARA, Calif.--(BUSINESS WIRE)--QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB), a leading provider of cloud enterprise resource planning (ERP) solutions and services for global manufacturers, today announced that Facet Technologies, a leading contract manufacturing organization, has deployed QAD Cloud ERP to meet current and anticipated production needs for manufacturing high-quality medical devices.
Facet, an FDA-registered, ISO 13485:2003-certified engineering and manufacturing company, specializes in manufacturing lancing devices, lancets for blood glucose testing and insulin injection pen needles for their global life science company customers. Facet was burdened by technology that did not have the capability to keep up with business needs. Many departments relied on spreadsheets for tracking and reporting. There were timing and accuracy issues when transactions were entered into the system and getting custom reports was frustrating and time-consuming.
Following a comprehensive search of potential technology solutions, Facet chose QAD Cloud ERP as the technology most capable of meeting current production challenges as well as future growth projections. Facet Technologies also chose Strategic Information Group (SIG) as its implementation partner based on SIG’s experience implementing QAD software, extensive knowledge of the life science industry, and proven track record. As a result of the deployment of QAD Cloud ERP, Facet has improved material requirements planning activities, reduced inventory carrying costs and eliminated errors associated with manual data entry.
“The new system is versatile, easy to use and required very little customization,” said Bobby Yeomans, Manufacturing Technology Director at Facet Technologies. “It is providing many positive results. These include helping lower inventory carrying costs and making more information readily available through new reports and browsers; allowing more people to make accurate decisions to improve business operations.”
One key selection element was QAD’s cloud-based, FDA-qualified IT infrastructure. “QAD’s qualified IT infrastructure provides clients with an environment that is in a demonstrable state of control and compliance. It is a key building block to help them ensure that they have a solid foundation upon which to base their software validation requirements. It is one of the primary drivers of the increase in cloud deployments by our life sciences customers,” stated Bart Reitter, Director of Marketing, QAD Life Sciences.
Facet’s future plans include implementing electronic data interchange (EDI), business intelligence (BI), enterprise asset management (EAM), supplier scheduling and additional data collection capabilities.
About QAD – The Effective Enterprise
QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB) is a leading provider of enterprise software and services designed for global manufacturing companies. For more than 30 years, QAD has provided global manufacturing companies with QAD Enterprise Applications, an enterprise resource planning (ERP) system that supports operational requirements, including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD Enterprise Applications is offered in flexible deployment models as on-premise software, in the cloud with QAD Cloud ERP or in a blended environment. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises.
For more information about QAD, call +1 805-566-6000, visit www.qad.com.
“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.
Note to Investors: This press release contains certain forward-looking statements made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding projections of revenue, income and loss, capital expenditures, plans and objectives of management regarding the Company’s business, future economic performance or any of the assumptions underlying or relating to any of the foregoing. Forward-looking statements are based on the company’s current expectations. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, “would”, “might”, “plan” and variations of these words and similar expressions are intended to identify these forward looking statements. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to: evolving demand for the company's products and companion products; the ability to sustain license and service demand; fluctuation in revenue and earnings in the software industry; the ability to leverage changes in technology; the ability to sustain customer renewal rates at current levels; third party opinions about the company; the reliability of estimates of transaction and integration costs and benefits; competition in our industry; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. For a more detailed description of the risk factors associated with the company, please refer to the company's latest Annual Report on Form 10-K, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission thereafter. Management does not undertake to update these forward-looking statements except as required by law.